MacroGenics, Inc. (MGNX)

NMS – Real Time Price. Currency in USD

4.03

+0.10 (2.68%)

Market open: Aug 12, 2026, 10:48 AM EDT

4.10

+0.18 (4.59%)

Previous after-hours: Aug 11, 2026, 7:34 PM EDT

11.08.2026

MacroGenics Announces Achievement of $10 Million Milestone Following Gilead's Exercise of Option to License Preclinical Bispecific Program

ROCKVILLE, MD, Aug. 11, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that Gilead Sciences, Inc. has exercised its option to obtain an exclusive license for a preclinical bispecific program under the companies' 2022 collaboration agreement. The option exercise triggers a $10 million payment to MacroGenics.

Videos

No Data

There is no data to display

Press releases

11.08.2026

MacroGenics, Inc. (MGNX)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

MacroGenics, Inc. (MGNX)

MacroGenics Announces Achievement of $10 Million Milestone Following Gilead's Exercise of Option to License Preclinical Bispecific Program

Videos

No Data

Press releases

MacroGenics Announces Achievement of $10 Million Milestone Following Gilead's Exercise of Option to License Preclinical Bispecific Program

MacroGenics Announces Achievement of $10 Million Milestone Following Gilead's Exercise of Option to License Preclinical Bispecific Program

Videos

No Data

Press releases

MacroGenics Announces Achievement of $10 Million Milestone Following Gilead's Exercise of Option to License Preclinical Bispecific Program

Search stocks

MacroGenics, Inc. (MGNX)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

MacroGenics, Inc. (MGNX)

MacroGenics Announces Achievement of $10 Million Milestone Following Gilead's Exercise of Option to License Preclinical Bispecific Program

Videos

No Data

Press releases

MacroGenics Announces Achievement of $10 Million Milestone Following Gilead's Exercise of Option to License Preclinical Bispecific Program

MacroGenics Announces Achievement of $10 Million Milestone Following Gilead's Exercise of Option to License Preclinical Bispecific Program

Videos

No Data

Press releases

MacroGenics Announces Achievement of $10 Million Milestone Following Gilead's Exercise of Option to License Preclinical Bispecific Program